Home | About the Academy | Library | Programs | Legal, Ethical & Professional Issues | Forum | Links | Contact | Guestbook
Origins | Organization | Presidents' Letters | Academy Members | Membership Form
Academy
for the Study of the
Psychoanalytic Arts
|
Psychopharmacology & the Government of the Self by
David Healy Here
is a picture of Jean Delay wearing the dark coat, along with Pierre Pichot on
his right and Pierre Deniker on his left, with Bernard Sadoun, Jean Thuillier
and Thérese Lemperière to Pichot’s right (Slide
1)[i]. Within the
walls of the hospital you see behind them, the ice has just melted -- literally.
Following the ideas of Henri Laborit, they had been giving chlorpromazine
as part of an effort to enable the body to be cooled down with ice, in the hope
that cooling would produce an anti-stress effect that would be useful in the
treatment of nervous problems. The
nursing staff observed that it made little difference whether chlorpromazine was
given with or without ice - it was beneficial either way.
Delay and his team had stumbled into the crucial discovery of the
antipsychotic effect of chlorpromazine, the discovery that underpins modern
psychiatry. The
spontaneity of the photograph is misleading however.
It almost suggests a father whose child has just been born and who is
rushing out to tell the world the good news. However, this is far from a
spontaneous photograph. There is a
rigid hierarchical arrangement here. Delay
is distinguished by his navy blue coat, which he and only he wore around the
university and hospital ground. When
he was later elected to the Académie Française, he would wear the ceremonial
sword that went with membership whenever possible.
He is talking to Pichot rather than to Deniker, the discoverer of
chlorpromazine because Pichot is, strictly speaking, the second most senior
person in the Department. This is a
hierarchical world in which, had an emissary been sent from a University
Department elsewhere in the world to visit Delay, even one considerably junior
to Pichot and Deniker, Deniker and Pichot would nevertheless have been summoned
to stand behind Delay while he talked to the emissary from elsewhere.
Possibly for up to an hour without their opinions being sought.
If the emissary had been from an ethnic minority, or was a woman or a
senior member of a pharmaceutical company it is unlikely that Delay would have
seen them. Women such as Hélène
Deschamps and later Ruth Koeppe were written out of the chlorpromazine story. There are
two things happening in the background, however, that will change everything,
unbeknownst to Delay and his group. Both
in North American psychiatry. In
the course of the Second World War, psychiatrists associated with the military
have discovered that group therapies can have a dramatic impact on the nervous
disorders produced in soldiers by the War.
These therapies work best it seems where they involve a dissolution of
the hierarchies of both preWar European social life and Army life.
This is particularly clear in Great Britain.
The more informal the setting, the better. American
military psychiatrists viewing this group therapy, in particular Karl Menninger,
take home a message. The options
were that groups work or that therapy works.
Menninger opted for a message of psychodynamic therapy works.
This led American psychiatrists returning from the War and also those
manning the asylums during the War to abandon the asylums and to set up office
practice. The asylums are left to
the Europeans. Power and influence
in American psychiatry uniquely moves into the community.
In so doing, American psychiatrists capture for psychiatry the vast range
of nervous and psychosomatic complaints that have previously been the province
of neurologists and internists with an interest in psychosomatic medicine. The other
thing that is happening stems from another war that began in 1914 - a War on
Drugs. This began with the
Harrison’s Narcotics Act, which made the opiates and cocaine available on
prescription-only. In 1951, a
Humphrey-Durham Amendment to the 1938 Foods Drugs and Cosmetics Act makes all
the new drugs produced by the pharmaceutical revolution following the Second
World War, the new antibiotics, antihypertensives, antipsychotics,
antidepressants, anxiolytics and other drugs, available on prescription-only. Not
everybody is happy with the new arrangement.
Many complain that a system designed for addicts is not appropriate for
the citizens of a free country. A
combustible set of ingredients has been put in place that will lead to an
explosion. It only took 16 years for the explosion to come. In slide
2, you see the Tokyo University on fire.
Tokyo sits at the apex of the Japanese hierarchy.
The students have occupied the Department of Psychiatry in an occupation
that continues for ten years. Psychiatric research in Tokyo is brought to a
halt. The most powerful psychiatrist in Japan, the professor of psychiatry in
Tokyo, Hiroshi Utena, is forced to retire. Why is
there such an extraordinary development? Only
16 years after the discovery of chlorpromazine, which liberated the insane from
their straitjackets. The great
boast of the advocates of chlorpromazine was that it had restored humanity to
the asylums. Previously,
lunatics had been guarded by jailers, who treated them brutally.
Now it was possible for therapists to see the humanity of their patients
and talk to them. The level of
noise in the asylum has fallen. However,
the times have seen the emergence of antipsychiatry and the antipsychiatrists
respond that real straitjackets have simply been replaced for chemical
straitjackets - the camisole chimique. That
indeed there is silence within the walls of the asylums, but this is the silence
of the cemetery. What is
happening? There is a revolution in
progress. A revolution that stems
in great part from the new drugs and the interaction between these drugs and the
social order in which people live. The
drugs have played or threaten to play a huge part in a changing of the social
order. The discovery of
chlorpromazine by Delay and Deniker was the discovery of a drug that acted on a
disease in order to restore a person to their place in the social order.
In contrast, Henri Laborit's discovery of chlorpromazine the previous
year, which led to artificial hibernation was the discovery of a drug which
produced an indifference, so that taking this kind of drug taxi drivers drove
through red lights. And out of
the same test tubes and laboratories from which chlorpromazine came, came LSD
and the psychedelics, Valium and the benzodiazepines and other drugs.
These were not drugs that restore people to their place in the social
order. These were drugs that had
the potential to transform social order. By 1968,
another drug, the oral contraceptive, had begun to transform the social order by
changing relations between the sexes (Slide
3). In 1968, for the first
time, the French clothing industry produced more trousers for women than for
men. By 1968, feminism had appeared
to challenge the colonisation of women's minds by men. 1968 saw
the culmination of a project begun by Rousseau and Voltaire, the Enlightenment.
This was a project, which overthrew the traditional hierarchical order in
society. It led to the dethronement
of kings and gods. It claimed that
the people should be ruled by the people and that an individual's place in
society should depend on merit. It
claimed that individuals had rights in addition to duties.
But this project had remained the preserve of white middle aged and
middle class men. It had not
extended to women, the young, ethnic groups, or others -- until 1968. In 1968,
antipsychiatrists and others protested against the colonisation of the minds of
ethnic groups by white Europeans (Slide
4), the colonisation of the poor by the rich, the colonisation of the minds
of the young by the old. They
castigated the new drugs as a means of controlling the young.
Madness was the protest of the colonised. Some of
the politics of the time can be seen if one considers the example of smart drugs
now. We live in a time now when it is not possible to discriminate on the basis
of sex, ethnicity, age or religion, but we still discriminate on the basis of
intelligence. Bright kids get to go
to good university and are subsidised by the state to do so. These cognitive
enhancers, it would seem, will bring benefits to less able or old animals
compared with young and bright animals. Should
cognitive enhancing drugs become available, they will favour those who are less
bright. Will they be made available
to society generally? Or will their
use to be restricted to diseases such as Aged Associated Memory Impairment? –
Can disease ever be a value free concept? The
anti-psychiatrists had a number of powerful weapons in their armoury.
One was ECT and the other was Tardive dyskinesia.
There is no question that ECT works – the problem with it and for
psychiatry was its visibility, which led to its pivotal role in the movie One
Flew over the Cuckoo’s Nest (Slide
5). Tardive dyskinesia was a
syndrome first described in 1960. By
1968, it was clear that it was a common and disabling side effect of
antipsychotic drugs. It was neither
the most common nor the most disabling side effect, but it was the most visible
(Slide 6). The
response from most of psychiatry was the same response as from psychoanalysts to
criticism against psychotherapy. When
the treatment failed to work, they claimed it was the disease, not the treatment
that was at fault. Similarly
psychiatry blamed the disease rather than the drugs.
Just as we have since done with the SSRIs and suicide. However,
the visibility of Tardive dyskinesia was a real problem and by 1974, SmithKline
& French had settled their first legal case for over $1million. With this
settlement, a generation of antipsychotic discovery, which includes drugs such
as chlorpromazine, thioridazine, levomepromazine, chlorprothixene, flupenthixol,
clopenthixol, haloperidol, droperidol, benperidol, perphenazine, fluphenazine,
prochlorperazine, trifluoperazine, pimozide, sulpiride and many others came to
an end. It was to be almost 20
years before another generation of antipsychotic drugs emerged.
When new drugs came, starting with clozapine, they came not because they
were better than the older drugs nor because they were good for negative
syndromes –whatever you think about the evidence for these claims, they were
not what led to the new generation of antipsychotics. The reasoning behind the
re-emergence of clozapine was because it didn’t cause tardive dyskinesia (Slide
7). Slide
8 shows Leo Hollister. In 1957,
Hollister had run a double-blind placebo-controlled trial of chlorpromazine in
patients with no nervous conditions at all, demonstrating that it produced
marked physical dependence. By
1966, a large number of studies had confirmed his observations that there was a
marked and severe physical dependence on antipsychotics that was present in
large numbers of people taking them, even at low doses for a relatively short
period of time. A dose of 1 mg Stelazine given for several months might produce
a state where the individual could never stop therapy ever again.
This led to the concept of therapeutic drug dependence.
A concept that blows a hole in most theories of addiction we have.
These drugs produce no tolerance, no euphoria.
They produce enduring post-discontinuation changes that are as extensive
and long lasting as the changes underpinning current disease models of addiction[ii].
But recognition of antipsychotic dependence vanished around 1968, when
the War on Drugs was declared. Psychopharmacology
was faced with a political problem. The
problem was how to distinguish drugs, which restored social order from drugs,
which subverted the social order. The
‘decision’ was made to categorise as problematic and dependence producing
any drugs, which subverted the social order.
This political rather than scientific decision set up a crisis a few
years later when physical dependence on the benzodiazepines emerged.
This broadened to an extraordinary crisis, which led to the obliteration
of the anxiolytics and indeed almost the whole concept of anxiolysis.
By 1990, physicians in Britain and elsewhere regarded benzodiazepines as
more addictive than heroin or cocaine – without any scientific evidence to
underpin this perception (Slide
9). You may
smile indulgently at this idea now, but the consequences could not have been
more profound. To appreciate these,
you simply need to look to Japan, where there never was a crisis with the
benzodiazepines. In Japan, the
concept of an anxiolytic remains respectable and the market for anxiolytics is
much greater than the market for antidepressants.
No SSRIs, not even "Prozac" are available on the Japanese
market for depression. The era of
Depression that we have lived through in the 1990s in the West has arguably been
a politically and economically constructed era that bears little relationship to
any clinical facts. An era that has
changed popular culture by replacing a psychobabble of Freudian terms with a new
biobabble about low serotonin levels and the like. As the
1990s ended, dependence on the SSRIs appeared.
Is another group of useful drugs going to be lost to us the way the
benzodiazepine were lost? Do we
understand enough about what happened to the benzodiazepines to be able to
guarantee that the SSRIs will not suffer the same thing?
Do we understand how the concept of dependence on antipsychotics could
have vanished just in time when a very obvious dependence syndrome -- Tardive
dyskinesia -- was causing so much grief to the psychiatric and pharmaceutical
establishments? If we don’t
understand what happened here, we can offer no guarantees for the future. Coming
from my perspective the antipsychiatrist arguments that madness doesn’t really
exist are simply wrong. But the
unarticulated force behind the antipsychiatrists’ arguments was that they
perceived that in some way the ways in which we govern ourselves had changed and
that psychiatry was now part of the new order of government.
Everyone agreed there had been a de-institutionalisation.
But was it a de-institutionalisation of patients?
Where patients are concerned, in Britain at least they are being detained
at 3 times greater rate than 50 years ago.
They were being admitted at a 15 times greater rate than before, and on
average, patients are spending a longer time in service beds than ever before in
history[iii].
New conditions such as personality disorders were being admitted to
hospital and the management of violence and social problems was becoming an
issue for psychiatry (Slide
10). The figures are more consistent with a de-institutionalisation of
psychiatry. Unselfconsciously,
psychiatrists claim we are treating more patients than ever before.
We are. This was
to lead to the greatest possible symbol for the times.
On the next slide, you can see the protests in Paris in 1968.
The students are on the march. Their
march takes them to the office of Jean Delay, which they ransacked.
Delay is forced to retire. He
has no sympathy for the new world, in which students can expect to address the
professors in informal terms (Slide
11). But the
fact that we are all here today suggests that we won, doesn't it?
You may not know how we won. No
history has ever been written of the period.
No textbooks of psychiatry record the sacking of Delay’s office.
None refer to the fact that the key figures behind the revolutions of
late 1960s, were psychiatrists or philosophers appealing to examples from
psychiatry -- Franz Fanon, Michel Foucault, R.D. Laing, Thomas Szasz, Erving
Goffmann, Herbert Marcuse. In the
face of a repression like this, you may feel that the ghost of Freud is hovering
somewhere, laughing at us, and perhaps you are right. The truth
is, we didn't win. The world
changed. Both psychiatry and
anti-psychiatry were swept away and replaced by a new corporate psychiatry.
Galbraith has argued we no longer have free markets; corporations work out what
they have to sell and then prepare the market so that we will want those
products (Slide 12)
[iv].
It works for cars, oil, and everything else, why would it not work for
psychiatry? Prescription only status makes the psychiatric market easier than
almost any other market – a comparatively few hearts and minds need to be won. Within
psychiatry, two factors have helped. One
was the emergence of Big Science. Look
at this graph from 1974, which shows the correlation between affinity for D-2
receptors and clinical potency. This
is one of the most famous images in modern psychiatry.
This version comes from Phil Seeman in Toronto (Slide
13). Solomon Snyder was doing
roughly the same at the time. This
was one of the triumphs of modern psychopharmacology.
It remains as true and accurate today as when it was first published 25
years ago. But these
binding data introduce something else as well, for which neither Seeman nor
Snyder, nor others who developed radiolabeled techniques can be held
responsible. They introduced a new
language, a language of Big Science, where physicians and companies had common
interests. Where previously
psychiatrists and antipsychiatrists and patients were using what was
recognisably the same language, this no longer applied after 1974.
Both sides had been governed by the visible presentations of the patients
in front of them. But after 1974,
to get into the debate you had to have a manifold filter and a scintillation
counter. Far from this being a
science that worked in the interests of patients, it led onto megadose regimes
of neuroleptics. No longer
answerable it seems to how the patients in front of us actually looked,
following the science we moved on to these megadose regimes that may have caused
as many brains to be injured as were ever injured with psychosurgery.
Science won’t necessarily save us, it must be applied with wisdom.
We have moved into an era when patients depend on their experts in a new
way – they depend on them to be genuine and conflict of interest begins to
play as an issue. Another
factor stems from figures like Rene Descartes, whom you can see in slide
14, Blaise Pascal and others, who were behind the development of statistics
and probability theory. It was this
that laid the basis for the Enlightenment.
A process began in the 18th century of mapping peoples rather
than just the land. This led on to
the notion of rule of the people by the people, as well as the creation of
social science and epidemiology. It
led to a moral movement in health and in psychiatry. The same
forces led at the end of 19th century to the first attempts to map
the human individual, their attitudes and abilities, personality, or
intelligence. Sales such as the IQ
scale led to new concepts of norms and deviations from those norms and
psychologists emerged to take a place in the educational system, the legal
system, and in the government of ourselves – it was this that underpinned the
psychodynamic revolution (Slide
15). This was
not just the replacement of theology and philosophy – the qualitative sciences
– by a new set of quantitative sciences.
The new statistics set up something else.
They set up a market in futures. A
market in risks. We were on our way
to becoming a Risk Society (Slide
16). In the case of the IQ test
for instance, deviations from the norm were now something that predicted
problems in the future. Parents
sought out psychologists in order to improve the futures for their children.
This was how we would govern ourselves in the future.
Through the marketplace[v]. Psychotropic
drugs entered this new market in many different ways.
The oral contraceptives for instance are clearly not for the treatment of
disease. They were a means of
managing risks. Where once, the
risks of eternal damnation had been those that concerned people the most, now it
was a much more immediate set of risks – indicating that we had switched one
set of future risks as the key ones that determined our behaviour for another
set more immediate set (Slide
17). The best selling drugs in
modern medicine do something similar – they don't treat disease.
They manage risks. This is
clearly true of the antihypertensives, the lipid lowering agents and other drug
(Slide 18).
It is true also of antidepressants, which have been sold on the back of
efforts to reduce risks of suicide (Slide
19). The
development of probability theory gave rise to the clinical trial.
We are now in an era, which is popularly portrayed as an "Evidence
Based Medicine" era. What can go wrong if we have clinical trial evidence
to demonstrate what works and what doesn't work, if we but adhere to this
evidence (Slide 20).
What more can we do than that? Arguably,
the term "Evidence Biased Medicine" would be more appropriate.
Clinical trials in psychiatry have never showed that anything worked.
Penicillin eradicated a major psychiatric disease without any clinical
trial to show that it worked. Chlorpromazine
and the antidepressants were all discovered without clinical trials.
You don't need a trial to show something works.
Haloperidol and other agents worked for delirium and no one ever thought
to do a clinical trial to support this. Anaesthetics
work without trials to show the point. Analgesics
work and clinical trials aren't needed to show this.
Clinical trials nearly got in the way of us getting fluoxetine and
sertraline. What
clinical trials demonstrate are treatment effects.
In some cases, these effects are minimal.
One may have to strain with the eye of faith to detect the treatment
effect. The majority of trials for
sertraline and for fluoxetine failed to detect any treatment effect.
This is not evidence that sertraline or fluoxetine do not work.
In clinical practice many of us are under no doubt that these drugs do
work. It is, rather, evidence of
the inadequacy of our assessment methods.
To show that something works, we would need to go beyond treatment
effects to show that these effects produce a resolution of the disorder in a
sufficient number of people to outweigh the problems such as dependence
syndromes that these drugs also cause. If
our drugs really worked, we shouldn't have 3 times the number of patients
detained now compared with before, 15 times the number of admissions and
lengthier service bed stays for mood and other disorders that we have now.
This isn't what happened in the case of a treatment that works, such as
penicillin for GPI. Aside from
the inadequacy of our clinical trial methods, professors of psychiatry are now
in jail for inventing patients. A
significant proportion of the scientific literature is now ghost written. A
large number of clinical trials done are not reported if the results don't suit
the companies' sponsoring study. Over
trials are multiply reported so that anyone trying to meta-analyse the findings
can have a real problem trying to work out how many trials there have been.
Within the studies that are reported, data such as quality of life scale
results on antidepressants have been almost uniformly suppressed.
To call this science is misleading. One of the
other aspects of the new medical arena is that the most vigorous and hostile
patient groups of the antipsychiatry period have been penetrated by the
pharmaceutical industry. Other
patient groups have been set up de novo by companies.
Part of the market development plans for many drugs these days include
the creation of patient groups to lobby on behalf of a new treatment.
Meetings are convened for pharmaceutical companies specifically to advise
and train on how to set up such groups. All of
this is perhaps part of the normal rough and tumble between clinical practice,
science and business. But these are
not the most important consequences for psychopharmacology of the development of
probability theory post-Descartes that I wish to pick up.
The critical development is contained in the following quote from Max
Hamilton: "it may be that we are
witnessing a change as revolutionary as was the introduction of standardization
and mass production in manufacture. Both
have their positive and negative sides" (Slide
21). Most of
you who have used Hamilton Rating Scale for Depression.
What is this man talking about when he talks about a revolutionary aspect
to using such a simple instrument as this.
Note the date. 1972.
Maybe Hamilton is close enough to the events that were happening at the
turn to see something that we cannot now see.
Maybe as a communist, he was sensitive to things that we are not
sensitive to now. Rating
Scales have been such feature of psychiatric trials and clinical practice for so
long now that it is perhaps difficult to see that there are revolutionary
aspects to what happened. There is
now a profusion of rating scales and checklists used throughout our schools and
all walks of life. We quantify
aspects of sexual behaviour, aspects of the behaviour of children, all sorts of
things we never quantified before. Where
once there was life’s rich variety, now children in our schools fall outside
all sorts of norms. And in the case
of children falling outside norms, we now have a range of data suggesting there
are things that parents can do to bring their children back inside appropriate
norms (Slide 22).
Things that we can do to minimise the risk for our children’s future.
Figures that just like the figures for IQ it is thought will generalise to the
population at large. The
figures on treatment effects from rating scales used in our clinical trials have
set up a new market. When you
consider that we are now treating children from the ages of 1 to 4 with
"Prozac" and "Ritalin", you will realise that we are not
treating diseases here. I have
written extensively on how corporations make markets but pharmaceutical
corporations have not sold psychotropic drugs to children.
The explosion of drug use in children is a manifestation of the force
that makes markets, that underpins the market development of pharmaceutical
companies and others. This is the
force that creates pharmaceutical companies.
The treatment effects from clinical trials have been taken to be findings
that generalise across the community – they are taken to indicate that these
agents will return children within the set of norms that will minimise future
risks. What parent could not want
to minimise future risks for their child. The eating
disorders perhaps offer an analogy for what is involved (Slide
23). Clearly people have
starved themselves for millennia. For
a variety of reasons, good and bad. Anorexia
nervosa emerged as something different to previous starving behaviors in the
early 1870s. No good
epidemiological figures exist for this next claim, as the epidemiology of eating
disorders didn't exist until recently, but the syndrome appears to have
increased in frequency in 1920s and 1930s and increased yet again in the 1960s
with new variants mushrooming. Competing
theories have focused on the possible psychodynamics of the problem, the biology
of the problem, or socio-political aspects of the problems.
These competing theories have rarely spoken to each other however. What is
rarely recognised is that in the 1870s Weighing Scales emerged and with them
norms for weight and deviations from the norm and an awareness that deviations
in the direction of what had formerly been thought to be healthy and beautiful
carried risks. The insurance
industry published and promoted these figures.
In the 1920s, Weighing Scales increased in frequency and the scales, with
their norms printed on the front of them, appeared in pharmacies, drug stores
and other retail outlets. In the
1960s, the Scales were miniaturised so that we all ended up with Weighing Scales
in our homes. Clearly
Weighing Scales don't create eating disorders in that even blind individuals can
become eating disordered. But it's
impossible to imagine eating disorders on the epidemic scale that now exist
without the presence of both Weighing Scales and modern normative ideas about
weight. And it is easy to imagine
the removal of the feedback from Weighing Scales as being in many cases
therapeutic in its own right. These
new figures and norms have been a means for women to govern their bodies. But the
selectivity of the figures also grounds a peculiarly modern neurosis. Just as
figures for GDP give us feedback from some areas of endeavour but not others and
in so doing encourage the promotion of automobiles and the chopping down of
trees, so also figures from this one area of life, which are easy to produce,
have the power to control behaviour. Markets
can be set up in other areas, such as air-quality and wilderness.
Until such time as they are, it requires great wisdom and considerable
internal resources to factor into our lives these other values. What is
the future? Well, there is bad and
good news. Although in truth, both
scenarios that I will outline may seem so strange that you may feel both of them
are bad. In Slide
24, you see the face of one of the greatest serial killers ever.
Perhaps the greatest serial killer of all time.
This man was a doctor. His
name, Harold Shipman. He worked
close to where I live. Shipman's
case illustrates that situations where trust is important can provide the
conditions for extraordinary abuses. One of the
conditions where trust applies is in prescription only arrangements, this
arrangement that was introduced for the bad drugs to restrict their availability
but now applies exclusively to the good drugs.
This arrangement was put in place so that physicians would quarry
information out of pharmaceutical companies on behalf of their patients and
would provide the counter-balancing wisdom to market forces. Since this
arrangement was first put in place, modern pharmaceutical companies and
corporations have grown to be the most profitable organisations on the planet.
There has been a change from companies run by physicians and chemists to
companies run by business managers who rotate in from Big Oil or Big Tobacco.
The companies are advised by the same lawyers who advise Big Oil and Big
Tobacco and other corporations. In the
case of tobacco industry, it now seems clear that the legal advice in the face
of the problems of smoking was not to research the hazards of smoking, as to do
so would increase the legal liabilities of the corporations involved (Slide
25)[vi].
Similar advice given to the managers of our pharmaceutical corporations
would be completely incompatible with prescription-only arrangements.
And the same lawyers who advise some of the pharmaceutical corporations
are the lawyers for the tobacco corporations.
In the case of Eli Lilly, Shook, Hardy and Bacon.
Advice like this would convert prescription-only arrangements into a
vehicle to deliver adverse medical consequences with legal impunity. I happen
to believe that Prozac and other SSRIs can lead to suicide.
These drugs may have been responsible for 1 death for every day that
"Prozac" has been on the market in North America.
In all likelihood many of you will not agree with me on this - you
haven’t seen the information that I have seen.
However we can all agree that there has been a controversy about whether
there may be a problem or not. What
I believe you will also have to agree with is the fact since the controversy
blew up, there has not been a single piece of research carried out to answer the
questions of whether "Prozac" does cause suicide or not.
Designed yes, carried out - no. How does
this apply to the future? Well with
the mapping of the human genome, we have the possibilities of creating new
markets (Slide 26).
We need this knowledge from the human genome to govern ourselves.
It will set up the markets that we need to govern ourselves.
It will tell us about some of the underpinnings to our beliefs - why we
believe some of the things we do in the religious and political domains. We need
this knowledge. But the products of
this research will belong almost exclusively to pharmaceutical corporations.
If they are advised in the way that they appeared to be advised at
present, this knowledge, which is so democratically important, will operate
against the interests of democracy. Finally,
you see here another image of the future (Slide
27)[vii].
In the course of the last 50 years, plastic surgery evolved into cosmetic
surgery. Plastic surgery began as a
set of reconstruction procedures aimed at restoring a person to their place in
the social order. It evolved into
cosmetic surgery when the reliability with which certain procedures could be
carried out passed a certain quality threshold. The word
"quality" has been pervasive in healthcare lately.
Quality in modern healthcare however does not refer to good interactions
between two human beings. Quality
as we hear it nowadays is being used in an industrial sense to refer to the
reproducibility of certain outcomes. Big
Mac hamburgers are quality hamburgers in this sense -- they are the same every
time. In the case of the
antidepressants, the quality is currently poor.
But the development of pharmacogenetics and neuroimaging is going to
change all that. It is not that our
drugs are necessarily going to be dramatically more effective, but the quality
of responses that we can produce is going to be much greater. Viagra
gives good indication of what will happen when we get to this stage.
Viagra is a drug that produces quality outcomes – reproducible
outcomes. When this happens, it
becomes possible to abandon the disease concept.
Pharmaceutical company executives and others talk openly instead about
lifestyle agents. This is the world
that lies in store for us. It is
not the world of traditional medicine, where drugs treat diseases to restore the
social order. It is a world in
which psychopharmacological interventions will potentially change that order.
Whether you should think this is good or bad is not for me to say.
I happen to think there may be many benefits. This
returns us to the picture of Delay and his colleagues (Slide
28). You remember I said that
Pichot and Deniker might be left standing behind Delay for an hour while he
entertained someone like me. This
was not an experience that Deniker or Pichot, however, experienced as some
exquisite form of torture or as a humiliation.
It was a different time. It
was a time when honour and loyalty were more important than they are now.
They counted for more than the search for individual authenticity we now
have. The hierarchy was something
that these men believed in. In the
same way, a fear of God was once seen as a good thing that held the social order
in place. This fear became anxiety
and then anxiety disorders – something to be treated. What this
shows is that there are forces at play, that can change not only the kinds of
drugs we give, not only the conditions we think we are treating, but our very
selves who are doing the giving. Forces
that can change us more profoundly that we can be changed by a handful of LSD
containing dust. For these reasons, you may think these changes deserve scrutiny. The alternative is to slide gently into the future. This seemed a viable alternative until recently when arguably the emergence of managed care has made it clear that sliding into the future may not be as gentle and painless as we might once have expected. [i] This lecture gives the outline of a forthcoming volume Healy D (2001). The Creation of Psychopharmacology. Harvard University Press. [ii] Tranter R, Healy D (1998). Neuroleptic discontinuation syndromes. J Psychopharmacology 12, 306-311; Healy D, Tranter R (1999). Pharmacologic Stress Diathesis Syndromes. J Psychopharmacology 13, 287-299. [iii] Healy D, Savage M, Michael P et al (in press). Psychiatric bed utilisation: 1896 and 1996 compared. Psychological Medicine. Lecture at 6th Hannah Conference on History of Psychiatry, Toronto April 17th 2001 – text available on request. [iv] Galbraith JK (1967). The New Industrial State. Penguin Books, Middlesex. [v] Rose N (1999). Powers of Freedom. Cambridge University Press. [vi] Glantz SA, Bero LA, Hanauer P, Barnes DE. The Cigarette Papers. University of California Press, Berkeley, 1996.
[vii] Haikan E (1999). Venus Envy. A History of Cosmetic Surgery. Johns Hopkins University Press.
Epilogue - One Side of the Background to an Academic Freedom Dispute
David
Healy Qualified from University College Dublin in 1979. Post-doctoral
degree on Biochemical Markers in Depression. Clinical Research Associate
in psychiatry in University of Cambridge 1986 – 1990. Reader in
Psychological Medicine in University of Wales College of Medicine, Director of
the North Wales Department of Psychological Medicine from 1992. Former
Secretary of the British Association for Psychopharmacology. Author of
over 120 peer reviewed articles and 12 books, including the reference history of
the antidepressants – The Antidepressant Era, Harvard University Press – and
The Creation of Psychopharmacology, Harvard University Press. Other books
include a three volume series of interviews – The Psychopharmacologists
Volumes 1-3. Correspondence: Email: Healy_Hergest@compuserve.com
|
Home | About the Academy | Library | Programs | Legal, Ethical & Professional Issues | Forum | Links | Contact | Guestbook
Origins | Organization | Presidents' Letters | Academy Members | Membership Form